TLDR: Dyno Therapeutics, a leader in AI-driven genetic technologies, has announced the launch of three new adeno-associated virus (AAV) capsid gene delivery vectors. These AI-designed capsids, Dyno-4z2 (eye), Dyno-3hv (neuromuscular), and Dyno-ahq (CNS), demonstrate superior delivery efficiency, target-organ specificity, and manufacturability in non-human primates. Concurrently, Dyno is hosting its inaugural Genetic Agency Technology Conference (GATC) on November 11, 2025, bringing together experts to foster collaboration and accelerate progress in gene therapy, with a strong focus on the role of AI and manufacturing advancements.
WATERTOWN, Mass. – Dyno Therapeutics, a pioneering genetic technologies company leveraging artificial intelligence (AI) to address the critical challenge of in vivo gene delivery, has made significant strides with the introduction of three novel adeno-associated virus (AAV) capsid gene delivery vectors. These breakthroughs, designed to enhance next-generation gene therapies for ocular, neuromuscular, and central nervous system (CNS) disorders, were unveiled at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 15, 2025.
The newly launched AI-designed capsids – Dyno-4z2, Dyno-3hv, and Dyno-ahq – have demonstrated remarkable improvements in delivery efficiency, precision targeting, and manufacturability in non-human primate (NHP) models. According to Eric Kelsic, Ph.D., CEO and Cofounder of Dyno, these optimized capsids will enable more efficient and specific delivery of therapeutic genes to the eye, muscle, and brain, pushing the boundaries of genetic medicine.
Key highlights of the new capsids include:
Dyno-4z2 for Eye Delivery: This capsid is engineered for highly efficient delivery to the retina via intravitreal (IVT) injection. It achieved over a 40-fold improvement in broad retinal transduction compared to AAV2 in NHPs and a 5-fold increase in bipolar cell transduction. Its ease of administration and compatibility with AAV2-based manufacturing processes promise broader patient access.
Dyno-3hv for Neuromuscular Delivery: Representing a significant advancement, Dyno-3hv is the first AAV capsid to show highly efficient delivery to multiple neuromuscular tissues, including the heart, skeletal muscle, and brain, from a single intravenous (IV) injection. It transduced 53-90% of skeletal myofibers and various heart and CNS regions in NHPs, while demonstrating liver detargeting with less than 10 vg/dg observed in the liver. It also identifies a novel receptor for blood-brain-barrier (BBB) crossing.
Dyno-ahq for CNS Delivery: Optimized for widespread and efficient CNS delivery via IV injection, Dyno-ahq achieved up to 30% neuronal transduction in NHPs after crossing the BBB, a 280-fold efficiency increase over AAV9. It also exhibited over 50-fold liver detargeting compared to AAV9, ensuring more targeted delivery to the brain. This capsid also leverages a novel, conserved BBB-crossing receptor.
These capsids, alongside previously released Dyno-86m and Dyno-hc9, are available for licensing to Dyno’s gene therapy partners, reinforcing the company’s commitment to solving in vivo delivery challenges.
In a related development, Dyno Therapeutics is set to host its inaugural Genetic Agency Technology Conference (GATC) on November 11, 2025, in Boston, Massachusetts. This one-day, invitation-only event will gather a diverse group of leaders, including therapeutic developers, technologists, AI pioneers, entrepreneurs, patients, and advocates. The conference aims to foster collaboration and accelerate the development of cutting-edge genetic technologies, with a strong emphasis on achieving ‘genetic agency’ – empowering patients to improve their health at a genetic level.
The GATC agenda features discussions on state-of-the-art AI for sequence design, gene editing, gene delivery, preclinical development, manufacturing, and regulatory pathways. Sessions like ‘AI-powered drug delivery: Unlocking programmable science’ and a panel on ‘The role of AI agents in the future of discovery, development and technologies that enable genetic agency’ underscore the central role of AI in Dyno’s vision. Eric Kelsic emphasized the need for collaboration among stakeholders to overcome bottlenecks in therapy development.
Also Read:
- Insilico Medicine to Showcase Advanced Generative AI Platform and Breakthrough Pulmonary Fibrosis Research at PFF Summit 2025
- Xunming Biotech Secures Multi-Million Series A Funding to Advance AI-Powered Antibody Design
Further supporting innovation, Dyno’s Frontiers Program offers technological and scientific support to select gene therapy developers. This program provides access to Dyno’s AAV capsid delivery vectors and expert advice on capsid selection, NHP study design, and vector manufacturing, enabling partners to demonstrate the in vivo effectiveness of their genetic payloads for eye, muscle, or CNS indications.
